Delta 9 Appoints David Kideckel as Head of Strategy, Corporate Development & Capital Markets

Published: August 18, 2021

Delta 9 Appoints David Kideckel as Head of Strategy, Corporate Development & Capital Markets

DELTA 9 CANNABIS INC. has appointed Dr. David Kideckel, PhD, MBA as Executive Vice President, Head of Strategy, Corporate Development & Capital Markets. This is a newly created position to lead the Company’s next phase of growth expansion.

David joins Delta 9 after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets. David’s industry experience spans several senior healthcare executive roles including at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca). Within Capital Markets, David was at the forefront of the cannabis industry and was the sole Bay Street analyst to cover GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), and was known for his expert analyses and thought leadership in retail, LP’s, US & international strategy & partnerships, as well as cannabinoid-derived pharmaceuticals and biosynthesis.

“I am extremely pleased to welcome David to our team, propelling our capital markets strategy and reach, through his wealth of experience. David was one of the leading cannabis analysts and has an exceptional network of contacts with an in-depth knowledge of the cannabis industry and its subsectors. David’s appointment reflects our commitment to having best-in-class talent to advance the Company’s growth trajectory strategically and expeditiously,” said John Arbuthnot, CEO of Delta 9.

“Of all the companies I have evaluated over the last several years, Delta 9 has incredible potential and I’m proud to join a seasoned team that is on the verge of steady and continuous growth within an explosive industry,” said David Kideckel, Delta 9 EVP, Head of Strategy, Corporate Development & Capital Markets.

About Delta 9 Cannabis Inc.
Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. The company sells cannabis products through its wholesale and retail sales channels and sells its cannabis grow pods to other businesses. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9’s shares trade on the Toronto Stock Exchange under the symbol “DN” and on the OTCQX under the symbol “DLTNF”. For more information, please visit